Domestic Surgical Robots

Toumai is the world's second endoscopic surgical robot approved for single-port surgery, after Intuitive Surgical's da Vinci. In April 2025, it demonstrated five-center simultaneous telesurgery — a single surgeon controlling robots in five different hospitals. By March 2026, it crossed 200 global orders across nearly 50 countries, including Spanish hospitals.

The significance is price disruption. Da Vinci systems cost $1.5-2.5 million each. Chinese surgical robots sell for a fraction of that, opening robotic surgery to hospitals in countries where da Vinci is unaffordable. In H1 2025, overseas orders for Chinese surgical robots exceeded da Vinci installations in China.

The tradeoff is track record. Da Vinci has been in clinical use since 2000, with millions of procedures performed. Toumai's clinical evidence base is growing but thinner. Surgeons and hospitals are conservative adopters — trust takes time to build.